NASDAQ: CFRX Navigate ContraFect Corporation HOME ABOUT US TECHNOLOGY PIPELINE INVESTORS & MEDIA CAREERS CONTACT US Profile Investors & Media Home Investors & Media Company Information Profile Investors & Media OVERVIEW NEWS / EVENTS PRESENTATIONS COMPANY INFORMATION PROFILE MANAGEMENT TEAM CONTACTS FAQ LOGOS FINANCIAL INFORMATION ANALYST COVERAGE STOCK DATA SEC FILINGS CORPORATE GOVERNANCE Email Alerts Tear Sheet Contacts RSS News Feed BUSINESS DESCRIPTION ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides. We believe DLAs provide the opportunity to make meaningful improvements to clinical outcomes and to change the treatment paradigm for patients infected with antibiotic-resistant bacteria. Our initial product candidates are new agents to treat lethal, resistant infections such as methicillin-resistant Staph aureus (MRSA) and Gram-negative pathogens like multi-drug resistant (MDR) Pseudomonas aeruginosa. COMPANY INFO Address: 28 Wells Avenue 3rd Floor Yonkers, NY 10701 US Telephone: 914-207-2300 Email: invest@contrafect.com INDUSTRY CLASSIFICATIONS Sector: Healthcare Industry: Biotechnology NAICS: Pharmaceutical Preparation Manufacturing (325412) SIC: Pharmaceutical Preparations (2834) © 2021 ContraFect Corporation. All Rights Reserved. COPYRIGHT PRIVACY POLICY EXPANDED ACCESS POLICY DISCLAIMER SITE MAP LINKEDIN TWITTER